Genitourinary Cancer

Nurse Takeaways: 2022 ASCO Genitourinary Cancers Symposium at a Glance

April 21, 2022

PARP inhibitors emerge as frontline treatment in metastatic castration-resistant prostate cancer, immunotherapy combinations improve quality of life in advanced renal cell carcinoma, and antibody drug conjugates show promise in cisplatin-ineligible urothelial cancer.